Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
ReViral
ReViral
X
LinkedIn
Trending Articles
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Broughton receives flexible scope ISO 17025 accreditation
New certification allows accreditation without prior approval
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Ingredients
ReViral appoints Alex Sapir as new CEO
Sapir will be based at North Carolina’s Research Triangle Park alongside the company’s new CMO, Seth Hetherington
Recruitment
ReViral appoints Dr Hetherington as Chief Medical Officer
The CMO appointment has been made as the company prepares its lead RSV candidate to enter phase II of clinical trials
Recruitment
ReViral announces appointment of new Chief Executive Officer
ReViral is an antiviral drug discovery and development company focused on novel antiviral treatments for diseases caused by the respiratory syncytial virus (RSV)
Subscribe now